Conservatives turn on Trump's Medicare IPI proposal

29 November 2018

A coalition of 55 Conservative groups and activists have voiced major concerns at US President Donald Trump’s proposals on Medicare drug prices.

Mr Trump and Alex Azar, Secretary for Health and Human Services, last month unveiled plans to create an international pricing index (IPI) payment model for drugs administered under Medicare Part B.

They promised that the model, which imports overseas price controls into the USA by modifying the Part B reimbursement rate so that it is calculated based on the prices set by 14 countries, would cut down on “foreign freeloading” and reduce US drug prices.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK